Indapamide is a thiazide-like diuretic.
It used in the treatment of hypertension, as well as decompensated heart failure.
Combination preparations with an ACE inhibitor antihypertensive are also available.
A non-thiazide diuretic, that lowers systolic blood pressure 54% more than HCTZ.
Indapamide does not have more adverse metabolic effects than HCTZ.
Has a longer half-life than hydrochlorothiazide and confers more antihypertensive potency and important effects that may include micro- and macrovascular benefits in patients with diabetes while it also reduced microalbuminuria.
Thiazide-like diuretics (indapamide and chlorthalidone) results in more reduction in the risk of major cardiovascular events and heart failure in hypertensive patients when compared with thiazide-type diuretics (hydrochlorothiazide) [12% and 21%. respectively] regardless the heterogeneity in age, sex and ethnicity and with comparable incidence of adverse events.
Thiazide-type and thiazide-like diuretics are effective in reducing stroke.
Combination preparations with other antihypertensives.
Pregnancy category AU: C.
Thiazide-type and thiazide-like diuretics have comparable rates of adverse effects as other antihypertensives such as angiotensin II receptor blockers and dihydropyridine calcium channel blockers and lesser prevalence of side-effects when compared to ACE-inhibitors and non-dihydropyridine calcium channel blockers.
Indapamide trade name Lozol.
Pregnancy category AU: C
Protein binding 71–79%.
Metabolism is hepatic.
Biological half-life 14–18 hours.
Indications-hypertension and edema due to congestive heart failure.
The adult dosage is 1.25 to 5 mg, orally and once daily, usually in the morning.
Indapamide is contraindicated in known hypersensitivity to sulfonamides, severe kidney failure, hepatic encephalopathy or severe liver failure, and a low blood potassium level.
Caution is advised in the combination with lithium.
Monitoring of potassium and uric acid serum levels is recommended.
Commonly reported adverse events are hypokalemia fatigue, orthostatic hypotension and allergic manifestations.
Routes of administration By mouth
Protein binding 71–79%
Elimination half-life14–18 hours.
Indications include: hypertension and edema due to congestive heart failure.
Indapamide has been shown to reduce stroke rates in people over the age of 52.
Systematic reviews find reductions in all cause mortality with thiazide-like diuretics, including indapamide, in octogenarians, as well as in young-elderly patients.
Indapamide is contraindicated: hypersensitivity to sulfonamides, severe kidney failure, hepatic encephalopathy or severe liver failure, and a low blood potassium level.
There is insufficient information about use in pregnancy or breastfeeding.
Adverse effects: low potassium levels, fatigue, orthostatic hypotension, and allergic manifestations.
Monitoring the serum levels of potassium and uric acid is recommended.
Use with lithium and drugs causing prolonged QT interval or wave-burst arrhythmia are to be used with caution..